文献速递认知障碍与痴呆

长程发作期Kleine-Levin综合征的静脉激素治疗

IV steroids during long episodes of Kleine-Levin syndrome.
PubMed 文献 · Neurology · 2018-03-23

该回顾性研究比较了长程Kleine-Levin综合征(KLS)发作期静脉甲泼尼龙(IV-MP)与不予干预的获益与风险。26例患者接受1 g/d IV-MP持续3天,共43次治疗;与48例匹配的未治疗患者相比,IV-MP组发作缩短至少1周的比例为42.3%,未治疗组为10.4%。在发作第10天前输注IV-MP时获益更明显(65.5%有效,发作缩短12天 vs 未治疗组0天)。

要点

  • IV-MP组42.3%患者发作较前次缩短至少1周,未治疗组仅10.4%
  • 发作第10天前给药获益更明显:65.5%有效,缩短12天 vs 0天
  • 61.3%患者报告轻度一过性不良反应,无躁狂转换

核心结论

  • 在这项开放标签自然观察研究中,对长程发作的KLS患者,早期IV-MP(参照多发性硬化复发方案)在发作期具有较好的获益/风险比,半数患者发作提前终止。
  • 该研究提供IV级证据表明,对于长程发作的KLS患者,静脉激素可缩短KLS发作持续时间。

研究设计与样本

  • 回顾性比较研究,26例KLS患者接受1 g/d IV-MP持续3天,共43次治疗,与48例年龄、性别、KLS起病年龄、发作次数及病程匹配的未治疗患者比较。

主要发现

  • IV-MP组11例(42.3%)发作较前次缩短至少1周,未治疗组缩短发作显著更少见(10.4%)。
  • 在发作第10天前输注IV-MP时获益更明显:65.5%有效,发作缩短12天 vs 未治疗组0天。
  • 61.3%患者报告轻度一过性不良反应(失眠、肌肉疼痛、紧张/不安),无躁狂转换。
  • 未识别出特定的有效者特征。

关键数值与推荐

  • IV-MP剂量为1 g/d,持续3天。
  • IV-MP组发作较前次缩短至少1周的比例为42.3%,未治疗组为10.4%。
  • 发作第10天前给药时有效率为65.5%,发作缩短12天 vs 未治疗组0天。
  • 轻度一过性不良反应报告率为61.3%。

临床怎么用

  • 作者认为,对长程发作的KLS患者,早期IV-MP(参照多发性硬化复发方案)具有较好的获益/风险比。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To retrospectively compare the benefits (episode cessation) and risks of IV methylprednisolone (IV-MP) vs abstention during prolonged Kleine-Levin syndrome (KLS) episodes. METHODS: A total of 26 patients with KLS received 1 g/d IV-MP for 3 days during 1 to 6 episodes each (totaling 43 IV-MP sessions). The change of episode duration with IV-MP (vs previous episode duration) was compared with the change duration between 2 consecutive episodes in 48 untreated patients matched for age, sex, age at KLS onset, number of episodes, and disease duration (more treated than untreated patients had long episodes). RESULTS: Eleven patients (42.3%) had an episode that was at least 1 week shorter than the preceding one when they received IV-MP therapy, whereas shorter episodes were significantly less frequent (10.4%) in the untreated group. This benefit was more marked (65.5% responders, 12 fewer days in an episode vs 0 days in the untreated patients) when IV-MP was infused before the 10th day of the episode. Mild, transient adverse effects (insomnia, muscle pain, nervousness/restlessness, but no manic switching) were reported by 61.3% of patients. No specific responder profile was identified. CONCLUSION: In this open-labeled, naturalistic study, early IV-MP (following the protocol for multiple sclerosis relapses) had a good benefit/risk ratio during KLS episodes in patients with long episodes (with half of the patients having an early cessation of episodes). CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with long episodes of KLS, IV steroids decrease the duration of KLS episodes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Léotard A, Groos E, Chaumereuil C, et al. IV steroids during long episodes of Kleine-Levin syndrome. Neurology. 2018. PMID: 29572278. doi:10.1212/WNL.0000000000005349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。